<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215761</url>
  </required_header>
  <id_info>
    <org_study_id>AFNET-B05</org_study_id>
    <nct_id>NCT00215761</nct_id>
  </id_info>
  <brief_title>Recurrence of Atrial Fibrillation in Patients With Dual-chamber Pacemakers and Drug Therapy</brief_title>
  <official_title>A Multicenter Study to Investigate Preventive Pacing in Combination With Antiarrhythmic Beta-Blocker Oder AT-I-/ACE-inhibitor Therapy on the Recurrence of Atrial Fibrillation in Patients With Dual-chamber Pacemakers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrial Fibrillation Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic BRC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrial Fibrillation Network</source>
  <brief_summary>
    <textblock>
      Comparison of AF-Burden in patients with paroxysmal atrial fibrillation and the necessity of&#xD;
      a Dual-Chamber-Pacemaker-Therapy either with a DDD[R]60-Stimulation or AF prevention pacing.&#xD;
      All Patients were stratified according to their existing drug therapy, e.g. Beta-Blocker or&#xD;
      ACE-Inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Implantable pacemaker devices are available with specific atrial pacing algorithms designed&#xD;
      to prevent atrial arrhythmias (Preventive stimulation). These algorithms work by increasing&#xD;
      the atrial pacing rate to achieve continuous overdrive pacing or by responding to triggers&#xD;
      such as premature atrial complexes.&#xD;
&#xD;
      Different investigation's showed that preventive atrial pacing was associated with a 30 to 50&#xD;
      % reduction in the risk of recurrence of AF, compared with no pacing. But a complete&#xD;
      recurrence-free long-term effect is not reached.&#xD;
&#xD;
      A hybrid therapy consisting of a combination of preventive atrial stimulation and&#xD;
      pharmacologic therapy maybe useful in restoring sinus rhythm. The HOPE-(Heart Outcomes&#xD;
      Prevention Evaluation)-Trial showed a overwhelming evidence that, in a broad range of&#xD;
      high-risk patients, an ACE-Inhibitor (Ramipril) prevents cardiovascular death, stroke, and&#xD;
      heart failure. AF leads to an activation of the renin-angiotensin system (RAS), which seems&#xD;
      to play an important role in atrial remodeling. Both experimental and clinical data have&#xD;
      confirmed the pro-arrhythmic role of the RAS and demonstrated an anti-arrhythmic effect of&#xD;
      ACE- and AT-I-Inhibitors. Madrid et al. showed that a combination of the AT-I-Inhibitor&#xD;
      irbesartan plus amiodarone decreased the rate of AF recurrences, with a dose-dependent&#xD;
      effect, in AF patients. ACE- and AT-I-Inhibitors represent new and efficient therapeutical&#xD;
      options to contrast the nearly inevitable progression of this arrhythmia towards its&#xD;
      permanent form. Beta-Blockers are a common pharmacologic therapy in AF patients.&#xD;
&#xD;
      The aim of the BACE-PACE-Trial is to investigate preventive pacing stimulation (PS) vs.&#xD;
      standard DDD[R]-60-Stimulation (ST) in combination with antiarrhythmic Beta-Blocker or&#xD;
      ACE-inhibitor therapy on the recurrence of atrial fibrillation in patients with dual-chamber&#xD;
      pacemakers&#xD;
&#xD;
      The Responder (patients without AF recurrence, respectively with a significant reduction in&#xD;
      AF burden) are compared to the standard stimulation. A clinically relevance meant a reduction&#xD;
      in AF burden of more than 25 % (experts consensus).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">263</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Paroxysmal symptomatic atrial fibrillation with implemented dual-chamber pacemakers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Paroxysmal symptomatic atrial fibrillation&#xD;
&#xD;
          -  Implantation of a dual-chamber pacemaker because of generally accepted pacing&#xD;
             indications&#xD;
&#xD;
          -  Symptomatic sinus bradycardia, sinus arrest, Tachy-Brady-Syndrome&#xD;
&#xD;
          -  Symptomatic sinuatrial block&#xD;
&#xD;
          -  Advanced AV-block (AV block II / III)&#xD;
&#xD;
          -  Binodal disease: Sick-sinus-syndrome and advanced AV-block&#xD;
&#xD;
          -  AV-Nodal-Ablation in combination with pacemaker therapy ( &quot;Ablate &amp; Pace&quot;).&#xD;
&#xD;
          -  The implantation of a fully functional DDDR Selection 9000, Prevent AF, T 70 DR&#xD;
             pacemaker (Vitatron) e.g. normal impedance, stimulation thresholds and sensing values)&#xD;
             2 - 4 months after implantation&#xD;
&#xD;
          -  Written informed consent of the patient&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic heart failure (NYHA III/IV)&#xD;
&#xD;
          -  Acute myocardial infarction &lt; 6 months&#xD;
&#xD;
          -  Hypertrophic obstructive cardiomyopathy&#xD;
&#xD;
          -  Symptomatic hypo- or hyperthyroidism&#xD;
&#xD;
          -  Instable angina pectoris&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Patients with diabetes mellitus and recurrent hypoglycaemia&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Participation in a clinical trial within the last 30 days. Simultaneous participation&#xD;
             in a registry (e.g. project AB1 of the AFNET) is permitted&#xD;
&#xD;
          -  Reduced life expectancy (&lt; 6 months)&#xD;
&#xD;
          -  Legal incapacity, or other circumstances which would prevent the patient from&#xD;
             understanding the aim, nature or extent of the clinical trial&#xD;
&#xD;
          -  Evidence of an uncooperative attitude&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Schuchert, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Cardiac Center, Hamburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Cardiac Center</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-vorhofflimmern.de</url>
    <description>German Atrial Fibrillation Network</description>
  </link>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 7, 2012</last_update_submitted>
  <last_update_submitted_qc>September 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Preventive stimulation</keyword>
  <keyword>Pacemaker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

